Gedeon Richter Researchers Publish Multiple Scientific Articles in 2024

Gedeon Richter Plc. has published numerous scientific articles in 2024, spanning a broad spectrum of research areas. The publications highlight the company's advancements in drug development and its ongoing investigation into previously introduced pharmaceuticals.

Key publications include research on a novel formulation of cariprazine orodispersible tablets, one of Richter's developed psychiatric medications. Another study addresses the coadministration of cariprazine with a moderate CYP3A4 inhibitor in schizophrenia patients, offering insights into dose adjustment and safety monitoring. Additionally, a study was published exploring the potential impact of cariprazine on latent and trait structures of symptoms in patients with schizophrenia.

The company's research portfolio also extends to new drug candidates. Novel cyclic malonamide derivatives have been synthesized and evaluated as selective RIPK1 inhibitors. Another study focuses on the development of V1A/V2 antagonists containing a triazolobenzazepine scaffold. Furthermore, new steroid-based histamine H3 receptor antagonists and inverse agonists have been discovered and characterized.

In addition to therapeutic advancements, Gedeon Richter's researchers have published articles detailing pharmaceutical manufacturing processes and analytical development. These include investigations into the effects of omitting titanium dioxide from tablet film coatings and the impact of high-shear mixing process parameters on the physical characteristics of powder blends. Real-time measurement of drug concentration during wet granulation using NIR and Raman spectroscopy has also been reported.

The research also delves into deeper pharmacology, such as the effects of the GLP-1 receptor agonist exenatide on food intake regulation in non-human primates and the elucidation of mechanisms for cariprazine targeting the D3 receptor.

These publications underscore Gedeon Richter's commitment to scientific inquiry and its sustained contributions to the pharmaceutical sector.